Clinical trials: Raynaud Phenomenon
Raynaud Phenomenon
Dermoscopy in Primary Raynaud's Phenomenon
Raynaud's phenomenon (RP) is very frequent in general population (up to 10%). Nailfold capillaroscopy (NFC) is recommended for patients presenting RP, to eliminate systemic disease such as systemic sclerosis.
- Trial name
- VASCUL-R (NCT04644523)
- Testing
- Dermoscopy
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Scleroderma, Raynaud's Syndrome
Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
This is a randomized, double-blinded, clinical trial assessing the therapeutic efficacy of Botulinum toxin A (Onabotulinumtoxin A) in treating scleroderma-associated Raynaud's syndrome.
- Trial name
- NCT02165111
- Testing
- Onabotulinumtoxin A, sterile saline solution
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Raynaud's Disease
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048776
- Testing
- Pletal
- Where
- 19 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Raynaud's Phenomenon
Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon
The purpose of this study is to evaluate the blood flow response to topical Glyceryl Trinitrate when applied to the skin of patient's fingers with Raynaud's Phenomenon.
- Trial name
- NCT00700518
- Testing
- Glyceryl Trinitrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Procris Pharmaceuticals
Raynaud Syndrome
Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome
The purpose of this study is to determine whether vardenafil is effective in improving clinical symptoms and peripheral blood flow in patients with primary and secondary Raynaud phenomenon.
- Trial name
- NCT01291199
- Testing
- vardenafil
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- University of Cologne
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
- Trial name
- NCT00378521
- Testing
- MQX-503
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics
Raynaud's Phenomenon, Systemic Sclerosis
The Effect of Physical Therapy on Raynaud's Phenomenon Secondary to Systemic Sclerosis
The effect of deep oscillation and biofeedback on Raynaud's phenomenon secondary to systemic sclerosis (SSc) remains to be determined.
- Trial name
- NCT00946738
- Testing
- Biofeedback, Deep oscillation
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Charite University, Berlin, Germany
Raynaud Phenomenon Due to Trauma, Raynaud Disease
Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud
Objective: To compare the efficacy of topical 10% nifedipine versus 5% sildenafil in patients with secondary Raynaud's phenomenon (RP).
- Conditions
- Raynaud Phenomenon Due to Trauma, Raynaud Disease, System; Sclerosis, Lupus Erythematosus, Systemic
- Trial name
- NCT03027674
- Testing
- 10% nifedipine cream, 5% sildenafil cream
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Systemic Sclerosis
CSL Behring Sclero XIII
Many patients with Scleroderma (Systemic sclerosis) experience damage to blood vessels, mainly to the small arteries. A common manifestation of this is Raynaud's phenomenon (fingers or toes turning white then blue in the cold)…
- Trial name
- NCT02551042
- Testing
- Fibrogammin®P, coagulation factor XIII concentrate (Human), 0.9% sodium chloride
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University College, London
Raynaud's Phenomenon
MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison
The purpose of this clinical study is to compare the pharmacokinetic profiles of a topical cream formulation of 0.9% nitroglycerin, MQX 503, and Nitroglycerin Ointment 2%, USP.
- Trial name
- NCT00841594
- Testing
- nitroglycerin 0.9 % (MXQ-503), Nitroglycerin ointment 2%, USP
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics
CREST Syndrome, Calcinosis Cutis
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
Background CREST is an acronym for the cardinal clinical features of the syndrome (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) and part of the heterogeneous group of sclerodermas.
- Conditions
- CREST Syndrome, Calcinosis Cutis, Raynaud Phenomenon
- Trial name
- NCT03972566
- Testing
- INOMAX
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- RoseLab Skin Optics Laboratory
Cold Hypersensitivity, Vascular System Injuries
Treatment of Frostbite Sequelae With Botulinum Toxin A
Background Digital vasospasm as part of frostbite sequelae is comparable to the vasospastic disorders found in Raynaud's phenomenon which has been successfully treated with Botulinum toxin type A injections in the palm of the…
- Conditions
- Cold Hypersensitivity, Vascular System Injuries, Vibration; Disorder, Sensory Disorders
- Trial name
- NCT06460194
- Testing
- Botuinum toxin
- Where
- Norway
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital of North Norway
Systemic Sclerosis
Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction
Purpose of the study is to evaluate the effectiveness and safety of a new investigational dur, IC351. Study is designed to gather information regarding the possible usefulness of IC351 as a treatment of several blood vessel…
- Trial name
- NCT00707187
- Testing
- Cialis
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Primary Raynaud's Phenomeon
Acupressure for the Treatment of Raynaud's Phenomenon
The use of acupressure will be compared to targeted Raynaud's education and will evaluate the' frequency, duration and pain of Raynaud's attacks.
- Trial name
- NCT01784354
- Testing
- Acupressure, Acupressure dilatation, education
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Systemic Sclerosis (SSc), Raynaud Disease Secondary to Scleroderma
Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad for the Treatment of Secondary Raynaud's Phenomenon
Raynaud's Phenomenon (RP), a vasospastic disorder causing digital ischemia and potential tissue necrosis, is effectively treated with Botulinum Toxin Type A (BTX-A) in refractory cases.
- Trial name
- Botox SSc-RP (NCT07759557)
- Testing
- Botulinum toxin A via microneedle, Control (Normal saline)
- Volunteers
- 72 people
- Sponsor
- Khon Kaen University
Scleroderma, Systemic Sclerosis
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand…
- Conditions
- Scleroderma, Systemic Sclerosis, Raynaud Phenomena, Raynaud's Disease
- Trial name
- STAR (NCT02396238)
- Testing
- Celution Device
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- Cytori Therapeutics
Raynaud
Tadalafil for the Treatment of Raynaud's
The investigators propose that tadalafil will increase digital blood flow and improve the symptoms and signs of secondary Raynaud's phenomenon.
- Trial name
- NCT00822354
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with…
- Trial name
- NCT04040322
- Testing
- Iloprost Injection, for intravenous use
- Where
- 30 sites in United States
- Volunteers
- 198 people
- Sponsor
- Civi Biopharma, Inc.
Raynaud's Phenomenon, Skin Necrosis
Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands
The purpose of this study is to evaluate the prognostic influence of light rheography measurement at the fingertips from subjects with secundary Raynaud syndrome.
- Trial name
- Anti-Vasospasm (NCT01378845)
- Testing
- Tracleer, Prostavasin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Christoph Hehrlein
Raynaud's Disease
A Two-Part Study of BOTOX® Therapy for Ischemic Digits
Treating patients with Raynaud's phenomenon who have chronic pain and ulcerations is extremely challenging. Published reports and our previous work support our hypothesis that symptomatic patients experience relief of pain and…
- Trial name
- NCT01309802
- Testing
- onabotulinum toxin type-A
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Southern Illinois University